• Study Resource
  • Explore Categories
    • Arts & Humanities
    • Business
    • Engineering & Technology
    • Foreign Language
    • History
    • Math
    • Science
    • Social Science

    Top subcategories

    • Advanced Math
    • Algebra
    • Basic Math
    • Calculus
    • Geometry
    • Linear Algebra
    • Pre-Algebra
    • Pre-Calculus
    • Statistics And Probability
    • Trigonometry
    • other →

    Top subcategories

    • Astronomy
    • Astrophysics
    • Biology
    • Chemistry
    • Earth Science
    • Environmental Science
    • Health Science
    • Physics
    • other →

    Top subcategories

    • Anthropology
    • Law
    • Political Science
    • Psychology
    • Sociology
    • other →

    Top subcategories

    • Accounting
    • Economics
    • Finance
    • Management
    • other →

    Top subcategories

    • Aerospace Engineering
    • Bioengineering
    • Chemical Engineering
    • Civil Engineering
    • Computer Science
    • Electrical Engineering
    • Industrial Engineering
    • Mechanical Engineering
    • Web Design
    • other →

    Top subcategories

    • Architecture
    • Communications
    • English
    • Gender Studies
    • Music
    • Performing Arts
    • Philosophy
    • Religious Studies
    • Writing
    • other →

    Top subcategories

    • Ancient History
    • European History
    • US History
    • World History
    • other →

    Top subcategories

    • Croatian
    • Czech
    • Finnish
    • Greek
    • Hindi
    • Japanese
    • Korean
    • Persian
    • Swedish
    • Turkish
    • other →
 
Profile Documents Logout
Upload
DEPARTMENT O F   HEALTH  AND  HUMAN ...
DEPARTMENT O F HEALTH AND HUMAN ...

... to be approximately 837, not 324.4819 as stated in the Notification. Because the chemical description of “AS1 Complex” in your notification was incomplete and inconsistent, FDA was unable to identify your new dietary ingredient. Because FDA could not determine the identity of “AS1 Complex,” it is no ...
Guideline on Fixed Combinations - EMA
Guideline on Fixed Combinations - EMA

Geometric Statistics in PK analysis - Programmer`s
Geometric Statistics in PK analysis - Programmer`s

... Both drug concentration data and pharmacokinetic parameters usually follow a skewed distribution among patient population. Reaction rate or a transfer rate of drug in a patient’s body are proportional to the amount of substrate available on a given time point. In most cases, an enzyme inhibitor will ...
lecture1-GENERAL PHA..
lecture1-GENERAL PHA..

... Different routes of administration are available Parenteral administration is the suitable route to provide rapid effect. I.V. is used in emergency and provide high availability Oral administration is best avoided during emergency or when severe first pass metabolism may occur Drugs may cross any ce ...
PPT
PPT

... Summary • Drug interactions are of great concern to both the pharmaceutical industry and regulatory agencies. • Major drug interactions are caused by either inhibition or induction of drug metabolizing enzymes. • Models provide numbers that must be placed in context with multiple factors: – therape ...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
UNITED STATES SECURITIES AND EXCHANGE COMMISSION

... MENLO PARK, Calif., February 25, 2016 -- Geron Corporation (Nasdaq: GERN) today reported financial results for the fourth quarter and year ended December 31, 2015 and recent events. Fourth Quarter and Year-End 2015 Results For 2015, the company reported net income of $46,000, or $0.00 per share, com ...
Pharmacokinetics - Christopher Hobbs
Pharmacokinetics - Christopher Hobbs

... • Traditional herbal formulas in traditional Chinese medicine (for instance) often includes 3-12 different herbs – Some are used to enhance the bioactivity of major actives – Also to act on different aspects of a disease process or symptom ...
Carrier transport
Carrier transport

TASK: Choose no more than SIX keywords that reflect the contents
TASK: Choose no more than SIX keywords that reflect the contents

... differences in dissolution rate, oral absorption, bioavailability, levels of gastric irritation, toxicology results, and clinical trial results. Ultimately both safety and efficacy are impacted by properties that vary among different solid forms. Stability presents a special concern, since it's easy ...
Generic Industry
Generic Industry

... It shall not be an act of infringement to make, use, offer to sell, or sell within the United States or import into the United States a patented invention (..)solely for uses reasonably related to the development and submission of information under a Federal law which regulates the manufacture, use, ...
Read "FDA Violation of the Rule of Law"
Read "FDA Violation of the Rule of Law"

... Roosevelt administration, feeling its oats after the "switch in time that saved nine," called for adoption of the Food, Drug and C osmetic Act of 1938. That law required companies to submit New Drug Applications (NDA's) before introducing new pharmaceuticals into interstate commerce. In concessions ...
Outsourcing API Manufacture to India & China A Suppliers Perspective
Outsourcing API Manufacture to India & China A Suppliers Perspective

... – >15 processes transferred to date including RSM, intermediates and launched APIs ...
FACTORS MODIFYING DRUG EFFECTS
FACTORS MODIFYING DRUG EFFECTS

... Since the activity of enzymes vary that can result in major difference in drug response This difference in liver activity may explain why women routinely wakes up from general anesthesia several minutes before a man given an equal dose. ...
Pharmacy Technician*s Course. LaGuardia Community College
Pharmacy Technician*s Course. LaGuardia Community College

Barclays Capital 2011 Global Healthcare Conference
Barclays Capital 2011 Global Healthcare Conference

... March 15 – 17, 2011 ...
Guidelines on Similar Biologic: Regulatory Requirements for
Guidelines on Similar Biologic: Regulatory Requirements for

Full Text
Full Text

... advertising spread.15 Compliance with these regulations limits the promotional claims that drug manufacturers can make in comparison with manufacturers of foods, cosmetics, or dietary supplements. While manufacturers of articles not classified as prescription drugs must still comply with the adverti ...
Clinical Data, Inc. Licenses Adenosine A2A Agonist to Santen for
Clinical Data, Inc. Licenses Adenosine A2A Agonist to Santen for

... and when, if at all, any such treatment will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether any treatment developed by Santen under our license agreement will be successfully marketed if approved; the str ...
SUSTAINED RELAEASE MULTIPARTICULATE DRUG DELIVERY
SUSTAINED RELAEASE MULTIPARTICULATE DRUG DELIVERY

... of the drug since multiparticulates are known to disperse freely in the gastric fluids covering greater surface of absorption. In addition they also offer benefits of reducing the dose required, and providing uniform drug delivery. So in the present study, attempts will be made to establish a optimu ...
Drugs Hanson 15
Drugs Hanson 15

Absorption - INAYA Medical College
Absorption - INAYA Medical College

Limitations of the Double-Blind Pharmaceutical Study
Limitations of the Double-Blind Pharmaceutical Study

0001104659-17-025291 - ContraVir Pharmaceuticals
0001104659-17-025291 - ContraVir Pharmaceuticals

... related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any drug candidates under development, there are significant risks in the development, regulatory approval, and commercialization of new products. There are no guarantees that future clinical tri ...
Herbal Compositions for Appetite Suppression and Weight
Herbal Compositions for Appetite Suppression and Weight

D Drug Discovery: A Historical Perspective
D Drug Discovery: A Historical Perspective

... does not, of course, include monoclonal antibodies, which today are produced in three different ways. They can be generated as mouse antibodies that are subsequently “humanized” by recombination with human antibody genes (30 –32). Alternatively, and perhaps preferably, human antibodies can be direct ...
< 1 ... 102 103 104 105 106 107 108 109 110 ... 193 >

Biosimilar

A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product which is a copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original ""innovator"" products, and can be manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.Unlike the more common small-molecule drugs, biologics generally exhibit high molecular complexity, and may be quite sensitive to changes in manufacturing processes. Follow-on manufacturers do not have access to the originator's molecular clone and original cell bank, nor to the exact fermentation and purification process, nor to the active drug substance. They do have access to the commercialized innovator product.Drug related authorities such as European Medicines Agency (EMA), Food and Drug Administration (FDA), and Health Canada hold their own guidance on requirements for demonstration of the similar nature of two biological products in terms of safety and efficacy. According to them, analytical studies that demonstrate that the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components; animal studies (including the assessment of toxicity); and a clinical study or studies (including the assessment of immunogenicity and pharmacokinetics or pharmacodynamics) that are sufficient to demonstrate safety, purity, and potency in one or more appropriate conditions of use for which the reference product is licensed and intended to be used and for which licensure is sought for the biological product.In case of a monoclonal antibody-containing medicinal product, such as Remsima, extensive physicochemical and biological characterization for it and its reference product Remicade was conducted in order to demonstrate their highly similar properties. Consequently, EMA have granted a marketing authorisation for only a few numbers of biosimilars since 2006 including a monoclonal antibody which is recently approved. Meanwhile, on March 6, 2015, the FDA approved the United States's first biosimilar product, the biosimilar filgrastim Zarxio.
  • studyres.com © 2025
  • DMCA
  • Privacy
  • Terms
  • Report